Literature DB >> 6383822

Inhibition of DNA binding of purified p55v-myc in vitro by antibodies against bacterially expressed myc protein and a synthetic peptide.

T Bunte, P Donner, E Pfaff, B Reis, I Greiser-Wilke, H Schaller, K Moelling.   

Abstract

To identify viral myc proteins, we have prepared myc-specific antibodies: (i) against a synthetic peptide corresponding to the nine carboxy-terminal amino acids of the viral myc (C9); (ii) against a bacterially expressed viral myc protein obtained by inserting the SalI-BamHI fragment of the viral MC29 DNA clone in the expression vector pPLc24. Both antisera recognize a protein of 55 000 mol. wt., p55v-myc, in MH2- and OK10-transformed fibroblasts. The protein is located in the nucleus, as shown by indirect immunofluorescence and cell fractionation. Antibodies against the C9 peptide were used to purify the p55v-myc by immunoaffinity column purification (3000-fold) from OK10- and MH2-transformed fibroblasts. p55v-myc binds to double-stranded DNA in vitro as does p110gag-myc. DNA binding in vitro is inhibited by the immunoglobulin fraction of antibodies against the bacterially expressed myc protein. Furthermore, a synthetic peptide consisting of 16 amino acids (C16) was used to isolate specific immunoglobulins which also inhibit DNA binding in vitro. OK10 codes, in addition to p55v-myc, for a p200gag-pol-myc polyprotein. The majority of this protein is located in the cytoplasm (79%). The purified protein binds to single-stranded RNA in vitro, unlike other gag-myc or myc proteins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6383822      PMCID: PMC557618          DOI: 10.1002/j.1460-2075.1984.tb02068.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  26 in total

Review 1.  Avian leukemia viruses: interaction with their target cells in vivo and in vitro.

Authors:  T Graf; H Beug
Journal:  Biochim Biophys Acta       Date:  1978-11-17

2.  Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis.

Authors:  K Bister; M J Hayman; P K Vogt
Journal:  Virology       Date:  1977-10-15       Impact factor: 3.616

3.  The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents.

Authors:  S Avrameas; T Ternynck
Journal:  Immunochemistry       Date:  1969-01

4.  Nuclear localization and DNA binding of the transforming gene product of avian myelocytomatosis virus.

Authors:  P Donner; I Greiser-Wilke; K Moelling
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

5.  Plasmid vectors for high-efficiency expression controlled by the PL promoter of coliphage lambda.

Authors:  E Remaut; P Stanssens; W Fiers
Journal:  Gene       Date:  1981-10       Impact factor: 3.688

6.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

7.  Molecular cloning of avian myelocytomatosis virus (MC29) transforming sequences.

Authors:  J A Lautenberger; R A Schulz; C F Garon; P N Tsichlis; T S Papas
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

8.  Mutants of avian myelocytomatosis virus with smaller gag gene-related proteins have an altered transforming ability.

Authors:  G Ramsay; T Graf; M J Hayman
Journal:  Nature       Date:  1980-11-13       Impact factor: 49.962

9.  Deletions within the transformation-specific RNA sequences of acute leukemia virus MC29 give rise to partially transformation-defective mutants.

Authors:  K Bister; G M Ramsay; M J Hayman
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

10.  Subgenomic mRNA in OK10 defective leukemia virus-transformed cells.

Authors:  S Saule; A Sergeant; G Torpier; M B Raes; S Pfeifer; D Stehelin
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

View more
  6 in total

1.  Two nuclear oncogenic proteins, P135gag-myb-ets and p61/63myc, cooperate to induce transformation of chicken neuroretina cells.

Authors:  P Amouyel; V Laudet; P Martin; R P Li; B Quatannens; D Stéhelin; S Saule
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

2.  Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins.

Authors:  K Strebel; E Beck; K Strohmaier; H Schaller
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

3.  Growth-dependent synthesis of c-myc-encoded proteins: early stimulation by serum factors in synchronized mouse 3T3 cells.

Authors:  H Persson; H E Gray; F Godeau
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

4.  Multiple growth-associated nuclear proteins immunoprecipitated by antisera raised against human c-myc peptide antigens.

Authors:  H Persson; H E Gray; F Godeau; S Braunhut; A R Bellvé
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

5.  Distinct and different effects of the oncogenes v-myc and v-src on avian sympathetic neurons: retroviral transfer of v-myc stimulates neuronal proliferation whereas v-src transfer enhances neuronal differentiation.

Authors:  H Haltmeier; H Rohrer
Journal:  J Cell Biol       Date:  1990-06       Impact factor: 10.539

6.  Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus.

Authors:  U R Rapp; J L Cleveland; T N Fredrickson; K L Holmes; H C Morse; H W Jansen; T Patschinsky; K Bister
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.